Alliqua Biomedical Inc (ALQA) : Zeke Capital Advisors has sold out all of its stake in Alliqua Biomedical Inc during the most recent quarter, according to the disclosure filed by the company on May 13, 2016 with the SEC. The investment management company has sold out 20,820 shares of Alliqua Biomedical Inc which is valued at $18,113.
Other Hedge Funds, Including , Vanguard Group Inc boosted its stake in ALQA in the latest quarter, The investment management firm added 66,520 additional shares and now holds a total of 518,516 shares of Alliqua Biomedical Inc which is valued at $451,109. Group One Trading sold out all of its stake in ALQA during the most recent quarter. The investment firm sold 3,588 shares of ALQA which is valued $3,122.Janney Montgomery Scott boosted its stake in ALQA in the latest quarter, The investment management firm added 10,000 additional shares and now holds a total of 84,500 shares of Alliqua Biomedical Inc which is valued at $73,515.Welch Forbes reduced its stake in ALQA by selling 21,724 shares or 63.86% in the most recent quarter. The Hedge Fund company now holds 12,292 shares of ALQA which is valued at $11,063.
Alliqua Biomedical Inc closed down -0.0139 points or -1.09% at $1.2561 with 62,067 shares getting traded on Wednesday. Post opening the session at $1.27, the shares hit an intraday low of $1.2392 and an intraday high of $1.28 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.
Many Wall Street Analysts have commented on Alliqua Biomedical Inc. Shares were Reiterated by Chardan Capital Markets on Feb 24, 2016 to “Buy” and Lowered the Price Target to $ 2.25 from a previous price target of $4.25 .Shares were Reiterated by RBC Capital Mkts on Feb 24, 2016 to “Outperform” and Lowered the Price Target to $ 3 from a previous price target of $6 .
Alliqua BioMedical Inc. is a provider of advanced wound care solutions. The Company’s businesses include advanced wound care and contract manufacturing. The Company operates through its subsidiaries AquaMed Technologies Inc. and Choice Therapeutics Inc. The Company is engaged in developing a suite of advanced wound care solutions that will enable surgeons clinicians and wound care practitioners to address the challenges in chronic and acute wounds. The Company utilizes hydrogel technology through which hydrogels are manufactured by introducing a hydrophilic polymer into water to create a feed mix. The Company’s commercial wound care portfolio consists of four product categories: Human Biologics; Antimicrobial Protection; Exudate Management and Contract Manufacturing. Human Biologics include BIOVANCE and Extracellular Matrix (ECM). Under Antimicrobial Protection the Company offers TheraBond 3D Antimicrobial Barrier Systems (TheraBond) and SilverSeal.